Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2 Wilms Tumor 1 Sarcoma 1 Prostatic Intraepithelial Neoplasia 1 Peripheral Nervous System Diseases 1 Neurotoxicity Syndromes 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Leukemia 1 Kidney Neoplasms 1 Dendritic Cell Sarcoma, Interdigitating 1 Carcinoma, Renal Cell 1 Burkitt Lymphoma 1

Interventions

Sunitinib 145 Nivolumab 144 pembrolizumab 132 Sorafenib 84 Bevacizumab 77 Everolimus 74 cabozantinib 71 pazopanib 65 Axitinib 65 Ipilimumab 62 aldesleukin 52 Magnetic Resonance Spectroscopy 45 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 37 Specimen Handling 36 Radiosurgery 36 Interferon-alpha 32 atezolizumab 30 temsirolimus 27 belzutifan 24 Gemcitabine 23 fludarabine phosphate 22 avelumab 22 Radiotherapy 19 Interferon alpha-2 19 Biopsy 18 fludarabine 17 durvalumab 17 Nephrectomy 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × Dietary Supplements × Genitourinary × Clear all

NCT05119010 2024-12-05

KETOREIN

Gustave Roussy, Cancer Campus, Grand Paris

Phase NA Terminated

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡